IXHL
NASDAQIncannex Healthcare Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks35+150%
2026-03-012026-08-23
Mix1490d
- SEC Filings6(43%)
- Other6(43%)
- Analyst1(7%)
- Leadership1(7%)
Latest news
25 items- PRIncannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42XNEW YORK and MELBOURNE, Australia, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today announced that the first patient has been dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X, the Company’s oral fixed-dose combination drug candidate for the treatment of obstructive sleep apnea ("OSA"). The milestone builds on the positive results from the Phase 2 RePOSA study, in which IHL-42X demonstrated statistically significant reductions in apnea-hypopnea index ("AHI") compared with placebo, with individual reduc
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- SECSEC Form SCHEDULE 13G filed by Incannex Healthcare Inc.SCHEDULE 13G - Incannex Healthcare Inc. (0001873875) (Subject)
- PRIncannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026NEW YORK and MELBOURNE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, today announced it has received the final A$5,102,788.30 refund under the Australian Government’s Research and Development Tax Incentive Program following approval of the Company’s overseas findings and amendment of its FY25 income tax return. Together with the previously announced A$6,039,162.43 refund, Incannex has now received more than A$11.2 million in non-dilutive capital during 2026. The receipt further enhances Incannex’s a
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep ApneaFirst clinical sites approved and actively screening potential participantsRepresents another major milestone in the advancement of IHL-42X towards Phase III developmentIHL-42X has received FDA Fast Track designation, highlighting its potential to address the significant unmet medical need in obstructive sleep apnea and supporting a potentially expedited regulatory pathwayStudy designed to optimize both objective sleep metrics and patient-reported outcomes to support regulatory approval and commercial differentiationBuilds upon previously announced positive Phase 2 data demonstrating up to 83% reduction in AHI and significant improvements across multiple patient-reported outcome measuresObst
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep ApneaMELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today announced that the United States Patent and Trademark Office (USPTO) has granted a key patent titled "Compositions and Methods of Treatment for Obstructive Sleep Apnea." The granted patent includes claims directed to the proprietary IHL-42X composition and its associated therapeutic methods for the treatment of Obstructive Sleep Apnea (OSA). The patent is expected to have a baseline expiry date of 9 July 2040 and the Company is expl
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial FlexibilityNEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, is pleased to announce that it has received A$6,039,162.43 under the Australian Government's Research and Development Tax Incentive Program. The Company also expects to receive an additional approximately A$5.1 million in future R&D Tax Incentive proceeds to be received in 2026. Combined, these proceeds represent more than A$11.1 million in non-dilutive capital that further strengthens the Company's balance sheet and enhances finan
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Announces Initiation of Research Coverage by Alliance Global PartnersMELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative combination therapies and next-generation medicines for high-impact indications, is pleased to announce that Alliance Global Partners ("AGP") has initiated equity research coverage of the Company. The research report, authored by AGP Managing Director and Senior Biotechnology Analyst James Molloy, provides an independent assessment of Incannex's clinical pipeline, development strategy, market opportunities and future growth prospects. Research Coverage Highlights Rating: BUYPrice Target:
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- ANALYSTAlliance Global Partners initiated coverage on Incannex Healthcare with a new price targetAlliance Global Partners initiated coverage of Incannex Healthcare with a rating of Buy and set a new price target of $18.00
- SECSEC Form 10-Q filed by Incannex Healthcare Inc.10-Q - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep ApneaMELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA). The commencement of DReAMzz represents a major operational and strategic milestone for the Company as it advances IHL-42X toward late-stage clinical development and potential registration pathways. The Company has now completed extensive site feasibility assessments, identified all 14 clinical trial sites, completed manufacturing
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug DevelopmentMELBOURNE, Australia and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced it has been named the winner of the "Best New Technology Solution for Drug Development" award in the 10th annual MedTech Breakthrough Awards program. The award recognizes Incannex's lead drug candidate, IHL-42X, an oral fixed-dose combination therapy in development for the treatment of obstructive sleep apnea (OSA), and reinforces the Company's growing position at the forefront of next-generation therapeutic innovation. IHL-42X combines dronabinol and a
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech BreakthroughLOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies and products in the global digital health and medical technology market, today announced that Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex"), a clinical-stage biopharmaceutical company leading the way in developing combination medicines, has been selected as winner of the "Best New Technology Solution for Drug Development" in the 10th annual MedTech Breakthrough Awards program. The award specifically recognizes the Company's lead drug candidate, IHL-42X, an oral fixed-dose combination therapy in development for
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental IllnessMELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the White House Executive Order signed by President Donald J. Trump on April 18, 2026, titled, "Accelerating Medical Treatments for Serious Mental Illness." The Company believes its PSX-001 development program aligns with the goals outlined in the Executive Order and believes the data demonstrated to date, along with a more amenable regulatory environment, may provide significant hope for those suffering from anxiety disorders. "We agree with the Administration's recognition that
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic PositionMELBOURNE, Australia and NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has reactivated its previously approved share repurchase program, with the program having been active over the past two trading days. The Company has utilized the buyback program opportunistically in the past, however had not actively repurchased shares in recent periods. The decision to reinitiate buyback activity reflects the Board of Directors' view that the Company's current market valuation does not accurately reflect the strength of its balance sheet, clinical prog
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
IXHL FAQ
6 questionsWhat does Incannex Healthcare Inc. do?
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as...Where does IXHL stock trade?
Incannex Healthcare Inc. (IXHL) is listed on NASDAQ.What sector and industry is IXHL in?
Incannex Healthcare Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IXHL?
Incannex Healthcare Inc. has had 1 recent analyst action on file. The most recent action was from Alliance Global Partners: Buy with a $1800.00 price target on 2026-06-08. Recent price targets cluster around $1800.00.What companies are similar to IXHL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IXHL side-by-side with any of them on Quantisnow.How can I track IXHL on Quantisnow?
Quantisnow aggregates Incannex Healthcare Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IXHL to receive live email and push alerts on every new disclosure.